Korea Price Cuts Could Trigger Reduced Big Pharma Investment
This article was originally published in PharmAsia News
Executive Summary
Price cuts initiated in April have hurt both multinational and local companies, and rather than trigger more R&D as hoped, the policy could dampen investment in Korea.